Our Company
Company
Company
Overview
We are an experienced team of scientists and drug developers who are motivated to improve the lives of patients through our expertise and scientific understanding of next generation, peripherally-acting CB1 receptor (CB1r) blockers.
Leadership Team
Corporate and financial executive with more than thirty years of experience in finance and administration roles with increasing responsibilities, including M&A, financing rounds, advisor to CEOs and CFOs. Trained in Business and Accounting at Concordia University (CPA and MBA degrees), she is recognized for her analyzing skills and rapid understanding of long-term corporate growth challenges.
Through her extensive experience in the biotech industry and other sectors, she developed an acute sense for nailing down sound strategies and identifying potential financial risks and opportunities.
Totally accustomed to key corporate areas such as budget, administration or forecasting, Micheline has been part of the comprehensive M&A process that led to the acquisition of Inversago Pharma by Novo Nordisk in August 2023, for up to 1.075 billion dollars US.
Jean-Daniel has more than 15 years as senior legal counsel with leading-edge experience in cross-border securities matters involving TSX, TSXV, and NASDAQ-listed issuers. Before joining Inversago in August 2022, Jean-Daniel started his career in private practice with a focus in business and securities law matters before joining Neptune Wellness Solutions Inc., and subsidiary Acasti Pharma Inc., where he served as Vice President, Legal Affairs and Secretary. Jean-Daniel is also a member of Anges Québec, Canada’s largest angel investor network, and a leader in the Quebec early-stage investment ecosystem. Jean-Daniel holds a law degree from the Université de Montréal and has been a member of the Quebec Bar since 2006.
Karine has 20 years of experience in clinical research operations, in roles with increasing responsibilities. Prior to joining the leadership team, Karine Lalonde was most recently Senior Director, Clinical Operations at Inversago. Previously at Ipsen, following the acquisition of Clementia Pharmaceuticals Inc., she contributed substantially to the NDA of palovarotene. Along her career, Karine acquired extensive experience in broad therapeutic areas ranging from diabetes to oncology and musculoskeletal rare diseases, including pediatric trials. Karine holds a MSc in clinical pharmacology from Université de Montréal.
